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Abstract
Background: Cancer survivors can face significant physical and psychosocial challenges; there is a need to identify
and predict which survivors experience what sorts of difficulties. As highlighted in the UK National Cancer
Survivorship Initiative, routine post-diagnostic collection of patient reported outcome measures (PROMs) is required;
to be most informative, PROMs must be linked and analysed with patients’ diagnostic and treatment information.
We have designed and built a potentially cost-efficient UK-scalable electronic system for collecting PROMs via the
internet, at regular post-diagnostic time-points, for linking these data with patients’ clinical data in cancer registries,
and for electronically managing the associated patient monitoring and communications; the electronic Patient-
reported Outcomes from Cancer Survivors (ePOCS) system. This study aims to test the feasibility of the ePOCS
system, by running it for 2 years in two Yorkshire NHS Trusts, and using the Northern and Yorkshire Cancer
Registry and Information Service.
Methods/Design: Non-metastatic breast, colorectal and prostate cancer patients (largest survivor groups), within 6
months post-diagnosis, will be recruited from hospitals in the Yorkshire Cancer Network. Participants will be asked
to complete PROMS, assessing a range of health-related quality-of-life outcomes, at three time-points up to 15
months post-diagnosis, and subsequently to provide opinion on the ePOCS system via a feedback questionnaire.
Feasibility will be examined primarily in terms of patient recruitment and retention rates, the representativeness of
participating patients, the quantity and quality of collected PROMs data, patients’ feedback, the success and
reliability of the underpinning informatics, and the system running costs. If sufficient data are generated during
system testing, these will be analysed to assess the health-related quality-of-life outcomes reported by patients,
and to explore if and how they relate to disease, treatment and/or individual differences characteristics.
Discussion: There is currently no system in the UK for collecting PROMs online and linking these with patients’
clinical data in cancer registries. If feasible, ePOCS has potential to provide an affordable UK-scalable technical
platform to facilitate and support longitudinal cohort research, and improve understanding of cancer survivors’
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experiences. Comprehensive understanding of survivorship difficulties is vital to inform the development and
provision of supportive services and interventions.
Background
Improving understanding of cancer survivors’ experiences
The UK National Cancer Survivorship Initiative (NCSI)
highlights a pressing need to improve understanding of
cancer survivors’ experiences and outcomes, through
increased collection of patient reported outcome mea-
sures (PROMs, i.e. questionnaires) in the years post-
diagnosis and treatment [1]. Research has highlighted
that some cancer survivors experience persistent physi-
cal and psychosocial difficulties, yet has also shown that
for many survivors quality-of-life is similar to the gen-
eral population [2-7]; as studies to date have mostly
examined limited short-term outcomes in small, non-
UK samples, knowledge about who experiences what
sorts of difficulties and when is limited [8,9]. Such
knowledge is crucial, however, to inform the develop-
ment and targeted provision of support services and
interventions. As cancer survivors are a large and grow-
ing group, targeting support toward those most in need
is increasingly important; although there are currently 2
million survivors in the UK, this is estimated to near
double by 2030 [10]. To gain a comprehensive under-
standing of survivorship, PROMs need to be repeatedly
collected from large numbers of patients, across multi-
ple health-related quality-of-life domains for many years.
To be of greatest use, PROMs also need to be linked
and analysed with patients’ diagnostic and treatment
information, as this will enable identification of clinical
predictors of survivorship difficulties, and thus facilitate
early risk stratification.
Overcoming the challenges of regularly collecting cancer
PROMs and linking with patients’ clinical data
A major challenge to large-scale, long-term PROMs col-
lection is cost. The expense traditionally incurred using
a paper-based methodology, however, can be reduced by
over 75% through use of a largely electronic and/or
internet-based system [11,12]; administering PROMs
online, communicating with patients via email, and
using a tracking database to semi-automate patient
monitoring and management, avoids the expense of
printing and postage and greatly reduces administrative
staff costs. Another key challenge to successful PROMs
collection is achieving high-levels of sustained patient
participation [13,14]. However, online PROMs may also
improve patient convenience, and thus participation and
retention; internet-PROMs can be completed at any
time of day, year-round, from patients’ homes, as well as
a growing number of web-accessible public locations
and mobile devices.
Very little cancer survey research includes a means to
link patients’ questionnaires with their clinical data [15];
linking clinical data with other information can be logis-
tically and ethically complex, time-consuming and
expensive [16]. However, there is potential to mitigate
the challenges of PROMs-clinical data linkage by using
the UK’s network of cancer registries which collate and
store clinical data on all cancer patients [17]; English
data are additionally pooled and stored by the National
Cancer Intelligence Network in the National Cancer
Data Repository (NCDR) [18]. Data linking via the regis-
tries/NCDR would capitalise on costly data collection
and validation work already undertaken, and allow
PROMs to be efficiently linked with a uniform dataset,
which is subject to the highest standards of governance
and security.
Designing and developing an electronic system for
regularly collecting PROMs online and linking with clinical
cancer registry data
To facilitate and support increased and improved mea-
surement of UK cancer survivors’ experiences, we have
designed and developed a technical system for regularly
collecting PROMs online, at repeated post-diagnostic
time-points, for linking and storing these with patients’
clinical data in cancer registries, and for electronically
managing the related patient monitoring and communi-
cations; the electronic Patient-reported Outcomes from
Cancer Survivors (ePOCS) system [19]. The PROFILES
Group (Patient Reported Outcomes Following Initial
treatment and Long-term Evaluation of Survivorship)
have very recently established a ‘web-based registry’ to
facilitate cancer PROMs collection in The Netherlands,
and which is linkable to clinical information in the
regional Eindhoven cancer registry [20]. In the UK,
however, there is currently no system for routinely col-
lecting cancer PROMs and linking with patients’ registry
data.
In the ePOCS system, patients complete PROMs using
a password-protected web-based questionnaire adminis-
tration tool (QTool), which is accessed via a public-
facing internet website (http://www.epocs.leeds.ac.uk),
and the responses are imported and stored with
patients’ clinical data in the registries/NCDR. Patients
click on PROMs listed on the QTool homepage, and
move through the questions by clicking a ‘Next Page’,
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and lastly ‘Submit’, button. Patients can return to par-
tially completed PROMs within 24 hours, and continue
from where they left off; after this time, PROMs are
automatically re-administered from the start. Submitted
PROMs cannot be reviewed. Patients receive PROMs
reminders if necessary, and thank you acknowledge-
ments on completion of all measures. At new data col-
lection time-points, patients receive invitations to go
online again and complete further PROMs.
Prior to the start of data collection, ePOCS system
administrators enter the required PROMs into QTool
and specify, for each, for which patients each question-
naire is available (e.g. prostate cancer), from what time-
point (e.g. 1 year post-diagnosis) and for how long (e.g.
3 weeks). During data collection, administrators track
patients’ PROMs activity and prepare and send related
communications using a password-protected electronic
tracking database (Tracker). The Tracker receives daily
information on patients’ PROMs completion progress
from the QTool, and using this, automatically generates
all necessary related correspondence (e.g. reminder
notices) by populating pre-prepared communications
with the relevant patient’s details (e.g. name, address).
Communications are generated, as appropriate, as
ready-to-send emails or ready-to-print letters; ePOCS
correspondence is entirely electronic for patients able
and willing to provide a contact email address. A more
detailed description of the ePOCS system, covering its
technical components, data flows and involved human
activities, can be found elsewhere [19].
Developing and testing the ePOCS system within a
context of hospital-based clinician-led patient recruitment
For any research involving PROMs collection, patients
must be identified as eligible, informed about the study
and provide consent. A system like ePOCS must, there-
fore, be able to receive information of newly recruited
patients, and be developed with a view to the context(s)
of recruitment. In the UK, it is not permitted to contact
patients directly through cancer registries, and research
suggests patient recruitment rates are generally higher
in secondary than primary care [21-23]. Furthermore,
we anticipate recruitment will be more effective and sus-
tainable if undertaken by clinical teams than by non-
NHS research personnel. In Yorkshire, where ePOCS is
being developed and tested, the electronic patient record
used in many hospitals is Patient Pathway Manager
(PPM), which contains a research database in which all
trials/studies are listed, all associated consented patients
are ‘tagged’ as such, and all related study events are
recorded (e.g. date of consent) [24]. The most efficient
means of supplying the ePOCS system with notice and
information about newly consented patients, from the
hospital-based recruiting clinical teams, will be via this
electronic record (i.e. via a daily automated data feed
from PPM to the ePOCS system). Therefore, we have
decided to develop and test ePOCS, at least in the first
instance, within a context of secondary-care based
patient recruitment, which is led by clinical teams (sup-
ported by research nurses), from hospitals using an elec-
tronic patient record (PPM).
Study aims
Primary aim
The primary aim of this study is to test the feasibility of
the ePOCS system, by running it for 2 years, in two
Yorkshire NHS Trusts, with non-metastatic breast, col-
orectal and prostate cancer patients (largest survivor
groups), and using the Northern and Yorkshire Cancer
Registry and Information Service (NYCRIS). System fea-
sibility will be examined primarily in terms of patient
recruitment and retention rates, the representativeness
of participating patients, the quantity and quality of the
collected PROMs data, patients’ feedback, the success
and reliability of the underpinning informatics, and the
system running costs.
Secondary aims
We also aim to analyse the PROMs data collected dur-
ing system feasibility testing. If ePOCS proves feasible,
and data of satisfactory quality are collected from a suf-
ficient number of patients, we plan to examine these
data for two main purposes: (1) to explore and check
the psychometric properties (e.g. reliability, validity) of
the newer, less well-established PROMs requiring of
further psychometric analyses, and (2) to assess and
describe patients’ self-reported health and quality-of-life
outcomes, and explore if and how they relate to disease,
treatment and/or individual differences characteristics.
Methods/Design
Study funding and approvals
This study is funded by Macmillan Cancer Support, and
is sponsored by the University of Leeds. The study pro-
tocol has received ethical and governance approvals
from the Leeds East NHS Research Ethics Committee
(ref. 10/H1306/65), and from the Leeds Teaching Hospi-
tals NHS Trust and Calderdale and Huddersfield NHS
Foundation Trust Research and Development Depart-
ments. Small amendments to the protocol, concerning
the methods of recruitment and the PROMs used, have
also subsequently been approved and are included in
this paper.
Study setting
Patients will be recruited from the Yorkshire Cancer
Network (YCN), which covers a population of approxi-
mately 2.6 million in the North and West Yorkshire
areas of England, UK. North and West Yorkshire
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include ethnically and socioeconomically diverse urban
and rural areas. Patients will be recruited from five hos-
pitals in the Leeds Teaching Hospitals NHS Trust,
which is the YCN Cancer Centre, and from two hospi-
tals in the Calderdale and Huddersfield NHS Foundation
Trust, which is one of six YCN Cancer Units.
Participants and sample size
Patients will be eligible for study inclusion if they are:
(1) over 17 years of age, (2) diagnosed with breast, col-
orectal or prostate cancer, (3) within the last 6 months,
(4) suitable for treatment with curative intent, and (5)
English literate. Patients will be excluded if they lack the
capacity to give informed consent (e.g. due to psycho-
pathology, cognitive dysfunction, learning difficulties).
The primary aim of the study is to test the feasibility of
the ePOCS system, and one of the key feasibility out-
comes is the number of patients who consent to join-up
(as a proportion of all those eligible and invited). The
recruited sample size is therefore an unknown outcome,
rather than a predetermined target; we aim to approach
all eligible consecutive patients and to recruit all those
who are willing to consent. However, we have estimated
that we may expect to recruit around 600 patients. The
number of adults newly diagnosed with breast, colorec-
tal or prostate cancer, within a recent 12 month period
at the two participating NHS Trusts, is almost 4,000
(specifically 3,839). However, many patients will not
meet the full eligibility criteria (e.g. some patients will
be non-English literate, unable to provide informed con-
sent etc.) (3,839 × .50 = 1,919), and we plan to recruit
patients for approximately eight months, rather than a
whole year (1,919 × .66 = 1,266). Previous similar
PROMs-based studies run by our research group have
yielded approximately 70% consent rates [25-28] (1,266
× .70 = 886), although not all patients will have suffi-
cient interest in and/or access to the internet to consent
to join ePOCS-most likely those without home access
[29] (886 × .70 = 620).
Patient Reported Outcome Measures (PROMs)
Patients will be asked to complete a range of generic,
cancer-specific and cancer diagnosis-specific PROMS,
representative of those likely to be administered in
future research studies which use the ePOCS system.
Patients will be asked to complete PROMs at three
time-points; as soon as possible after consent (≤ 6
months post-diagnosis; T1), 9 months post-diagnosis
(T2), and 15 months post-diagnosis (T3). The specific
measures are detailed below, and assess a variety of
health and quality-of-life domains, including pain, fati-
gue, psychological well-being, physical, social and sexual
functioning and financial concerns.
Illness Perception Questionnaire-Revised (IPQ-R)
The IPQ-R [30] assesses patients’ personal beliefs and
expectations about their illness (e.g. about its controll-
ability and consequences), and can be adapted to assess
perceptions about any illness (i.e. in this instance, can-
cer). The IPQ-R comprises nine subscales, eight of
which will be used in this study; the ‘causes’ subscale
will be omitted due to concern from patients on our
study steering group that enquiring about the (per-
ceived) causes of a patient’s cancer would cause distress;
this use of subscales is valid (Moss-Morris, personal
communication, 1 July 2010). The IPQ-R (minus the
causes subscale) comprises 38 statements (e.g. “my can-
cer is a serious condition”, “my cancer will improve in
time”) rated on a scale of 1 (strongly disagree) to 5
(strongly agree), and 14 symptoms (e.g. ‘breathlessness’,
‘headaches’) rated on a yes (1)/no (0) scale, with respect
to patients’ views at the present moment. The IPQ-R,
and its predecessor the IPQ [31], have been shown to
be reliable and valid, and to predict various aspects of
illness adaptation and recovery, in a range of samples
including cancer patients [30,32-37]. Patients will be
asked to complete the IPQ-R at T1.
EuroQol-5D (EQ-5D), version 2
The EQ-5D [38,39] is a 6-item generic measure of
health status which assesses mobility, self-care, usual
activities, pain/discomfort and anxiety/depression, using
a three-option response format according to the severity
of problems experienced that day (no problems, some
problems, severe problems). The EQ-5D also includes a
visual analogue scale on which health state today is
rated from 0 (worst imaginable health state) to 100 (best
imaginable health state). The EQ-5D is an internation-
ally used measure, that can be employed in both the
clinical and economic evaluation of health care, and
which has been shown to be reliable and valid in several
previous studies with cancer patients [40-43]. Patients
will be asked to complete the EQ-5D at all three time-
points.
Medical Outcomes Study 36-item Short-Form Health Survey,
version 2 (SF-36v2)
The SF-36v2 [44] is a generic measure of health status and
functioning which assesses eight domains including physi-
cal functioning, pain and mental health. The measure
comprises 36 items (e.g. “have you been happy”, “did you
feel worn out”) rated on a variety of Likert-type response
scales (e.g. excellent - poor, all of the time - none of the
time), primarily with respect to the past 4 weeks. The SF-
36v2, and its predecessor the SF-36, are internationally
used measures with extensive normative data, and have
been demonstrated reliable and valid in numerous pre-
vious studies with cancer patients [45-50]. Patients will be
asked to complete the SF-36v2 at T2 and T3.
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European Organisation for Research and Treatment of
Cancer (EORTC) Quality of Life Questionnaire (QLQ), version
3
The EORTC-QLQ [51] is a cancer-specific measure
assessing health-related functioning and symptoms,
which includes a generic core questionnaire and numer-
ous diagnosis and treatment specific modules. This
study will use the breast (EORTC-QLQ-BR23), colorec-
tal (EORTC-QLQ-CR29) and prostate (EORTC-QLQ-
PR25) modules, each of which contain between 20 and
27 questions (depending on item branching). In addition
to the relevant diagnosis-specific module, patients will
be asked to complete six subscales from the core ques-
tionnaire (nausea and vomiting, dyspnoea, insomnia,
appetite loss, constipation and diarrhoea; 7 items), and
two from the ovarian module (peripheral neuropathy
and chemotherapy side effects; 7 items); this use of sub-
scales is acceptable (EORTC, personal communication,
19 July 2010). All EORTC-QLQ items (e.g. “did you
have a dry mouth”, “has weight gain been a problem for
you”) are rated on a scale of 1 (not at all) to 4 (very
much) with respect to the past week or month. The
EORTC-QLQ is an internationally used measure with
sound psychometric properties [5,25,51-54]. Patients will
be asked to complete the EORTC-QLQ modules and
subscales at T2 and T3.
Social Difficulties Inventory (SDI-21)
The SDI-21 [27] assesses various everyday difficulties
commonly experienced by cancer patients, including
relationship difficulties, domestic problems and financial
worries; 21 questions (e.g. “have you felt isolated”, “have
you had any financial difficulties”) are answered on a 0
(no difficulty) to 3 (very much) scale with respect to the
past month. The SDI-21 has been demonstrated reliable
and valid, has a clinically meaningful scoring system
(including cut-off and minimal change scores indicative
of need for action), and is highlighted in the NCSI as a
potentially useful screening measure [1,27,28,55].
Patients will be asked to complete the SDI-21 at T2.
Quality of Life in Adult Cancer Survivors (QLACS) scale
The QLACS [56] measures health-related quality-of-
life in seven generic and five cancer-specific domains,
including cognitive problems, social avoidance and
appearance. QLACS comprises 47 items (e.g. “you felt
tired a lot”, “you had difficulty doing activities that
require concentrating”) rated on a scale of 1 (never) to
7 (always) with respect to the past 4 weeks. QLACS is
a relatively new measure, although is flagged as poten-
tially useful in the NCSI, and evidence to date indi-
cates acceptable psychometric properties in samples
including breast, colorectal and prostate cancer
patients [1,56-58]. Patients will be asked to complete
the QLACS at T3.
Sociodemographic details (and clinical information)
Patients will be asked to provide information about their
ethnicity, relationship status and level of education at
T1. Other sociodemographic details (e.g. gender, age,
postcode) and clinical information (e.g. date and type of
cancer diagnosis, treatment regimens) will be obtained
from participants’ medical records (following their expli-
cit permission, recorded on the consent form).
Employment status
Patients will be asked one question about their pre-diag-
nosis employment status at T1 (e.g. full-time employ-
ment, retired), and two questions about their current
employment status at all three time-points (e.g. full-time
employment, retired, currently working less or more
hours than usual).
Past use of mental health services
Patients will be asked two questions about their past uti-
lisation of mental health care services at T1; questions
enquire about lifetime use, and use over the last 12
months, and originate from the National Comorbidity
Survey [59-61].
Recent use of health and social services
Patients will be asked 20 questions about their use of
health and social services at T3. The questions have
been devised with health economist colleagues from the
University of Leeds, and aim to help estimate some of
the financial costs of cancer and its treatment, both to
patients and the welfare state. Questions enquire about
patients’ frequency of use of medications and services
(e.g. district nurses, social workers, residential homes,
hospices), and the cancer-related costs incurred by
patients and carers (e.g. due to increased home-heating
costs, and travel and time off work for hospital appoint-
ments), over the last 3 months.
Patient feedback on the ePOCS system
At the end of the study, participants will be offered the
opportunity to provide comment on the ePOCS system
through a ‘feedback questionnaire’ containing a mix of
28 closed and open questions (e.g. “what did you like
about the electronic questionnaire system”, “would you
have preferred to complete the questionnaires on
paper”). For patients who join the feasibility study and
use the ePOCS system to complete PROMs, we want to
know about their experiences, and whether they have
any suggestions for the system’s improvement. For
patients who join the study but do not go online and
complete (all the) PROMs, we would like to know if
there were any system-related reasons for this, and if
there are things we can change to make the system
easier to use. It will be important to keep feedback on
the system distinct from the system itself, and to include
those patients who may join the study but do not in fact
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engage with the system and complete PROMs. There-
fore, all consented patients (who have not actively with-
drawn from the study) will be posted a paper copy of
the feedback questionnaire, after completion of the T3
PROMs (or after the time-window for completion has
expired). To minimise burden, a pre-paid addressed
envelope will be included for return, and non-returns
will not be followed-up with reminders.
Procedures
Patient recruitment
Recruitment will be undertaken by oncology clinical
care teams, at the two participating NHS Trusts, sup-
ported by dedicated research nurses funded by the West
Yorkshire Comprehensive Local Research Network. Eli-
gible patients will be identified during discussions in
routine MDT meetings and/or through consultation of
medical notes. All eligible patients will be given a com-
prehensive information sheet containing the contact
details of the ePOCS study team, and which emphasises
the voluntary nature of participation, and patients’ right
to withdraw consent, at any time, without the need for
explanation, and without their personal care being
affected. Patients who wish to join the study will be
asked to read, complete and sign a consent form; this
will be countersigned by the recruiting research nurse/
clinician, and a copy filed in patients’ medical notes.
Participants’ General Practitioners will be sent a letter
informing them of their patients’ participation in the
study. Clinical care teams will provide anonymous infor-
mation about those patients who decline to participate
(gender, age, postcode, date and type of cancer diagno-
sis); if forthcoming, the recruiting teams will also note
any reasons offered by patients for non-consent (e.g.
lack of time, no interest in computers).
Prior to this study, we conducted a small opinion-
gathering interview study (NHS Research Ethics Com-
mittee ref. 09/H1313/73) to obtain advice from oncology
clinicians and patients about the ‘best’ time and person
in secondary care to approach patients about joining
ongoing PROMs-based research. Following the strong
unanimous views expressed in that study, patients will
first be approached about participation in the current
feasibility study by an oncology clinician with whom
they are familiar (e.g. consultant, registrar, specialist
nurse) and, if possible, with whom they have established
a ‘good relationship’. Wherever possible, patients will be
approached about the study in-person, typically during a
routine outpatient appointment; if this is not possible,
patients will be sent a letter about the study, signed by
their consultant. Perhaps unsurprisingly, given that
every patient is an individual, and every care pathway is
unique, opinion in the interview study did not converge
on a single best time for approach. Clinicians and
patients did, however, agree on what were non-optimal
times; notably, very close to the time of diagnosis (i.e.
within a few weeks), and when patients are facing
uncertainty (e.g. when the treatment course is yet to be
decided, when the results of a short-term intervention
like surgery are as yet unknown). The general consensus
was that patients several weeks out from diagnosis, who
are well-embarked on a decided course of treatment,
will be open to receiving information about the study.
However, the exact time-point when this will be (e.g. 4
weeks or 3 months post-diagnosis) will differ for each
patient. The clinical teams recruiting patients will use
the findings from our preparatory interview study to
inform and guide their recruitment approach.
Patient participation
Consenting patients will be given a unique ID and pass-
word on a postcard, which contains instructions for
accessing the ePOCS website and our study team’s con-
tact details. Patients will be asked to log-on to the
ePOCS system and complete the T1 PROMs as soon as
possible. Patients will then be sent an email or letter
(depending on their preferred mode of correspondence)
when they are approaching (i.e. 3 weeks before) 9
months (T2) and 15 months (T3) post-diagnosis, invit-
ing them to log-on to the system and complete PROMs
again. At each time-point, patients will have up to 6
weeks to complete the PROMs (i.e. 3 weeks either side
of the exact time-point; aside from the first time-point,
which is variable, as patients will be recruited at any
time within 6 months post-diagnosis). Up to two email/
letter reminders will be sent to patients who do not
complete the PROMs. For all PROMs questions,
patients will have the option to respond ‘I would prefer
not to answer this question’. Completion of the PROMs
at each time-point is likely to take approximately 20-30
minutes in total; patients can spread-out completion if
they wish (e.g. over a number of days). All correspon-
dence will remind patients that their PROMs responses
are not fed back to their clinical team, and to contact
their doctor or nurse if they have any problems or con-
cerns about their health. The study website also contains
links to relevant supportive organisations (e.g. Macmil-
lan Cancer Support, Prostate Cancer Charity). At the
end of the study, patients will be sent a paper feedback
questionnaire inviting their thoughts and opinions on
the ePOCS system.
System administration
Members of our study team will administrate the
ePOCS system during feasibility testing. We will use the
Tracker on a daily basis to monitor patients’ PROMs
completion progress, and to prepare and send the neces-
sary related communications (e.g. reminder notices,
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thank you acknowledgments). Our study team will also
be accessible to patients (via email, telephone and/or let-
ter) to provide assistance with using the ePOCS system.
The current feasibility study is funded for 2 years. If
the ePOCS system proves feasible, we would like to
expand the research by, amongst other things, following
patients for longer than 15 months post-diagnosis. If we
obtain further funding to do this, we would like to invite
the patients who participate in this feasibility study to
join our future studies (and complete more PROMs at
longer-term follow-ups). We will explicitly seek patients’
permission to contact them in the future (for up to 10
years after the study) if we obtain further funding-to
inform them about, and to seek their consent to partici-
pate in, new ePOCS-related research studies. Patients
will be informed of this via the study information sheet,
and if they give permission for future contact, will be
asked to sign a separate statement on the consent form
to indicate this.
Study outcomes and data analysis
Primary outcomes
The feasibility of the ePOCS system will be assessed by
examining a number of different outcomes. Notably: (1)
the proportion of patients recruited into the system, and
their representativeness, relative to all those invited to
join, (2) the proportion and representativeness of
patients who remain in the system and complete
PROMs at the different time-points, relative to all those
who join, (3) the completeness, timeliness and reliability
of the PROMs data obtained at each time-point (e.g.
extent of missing responses, internal reliability of
responses), (4) patients’ views and opinions on the sys-
tem provided via the feedback questionnaire, (5) the
success and reliability of the underpinning informatics
(e.g. frequency and nature of technical problems, fre-
quency and nature of patient enquiries requesting assis-
tance in using the system), and (6) the system running
costs. The efficiency and practicality of the patient
recruitment procedures (i.e. hospital-based clinician-led
recruitment) will also be examined.
The different feasibility outcomes will be primarily
analysed quantitatively using descriptive statistics such
as proportions, frequencies and means (e.g. proportion
of invited patients who consent, frequency of patient
requests for help with using the system, mean running
costs per month), chi-square and t-tests (e.g. to examine
group differences in gender, age etc. between consenters
and non-consenters) and measures of internal reliability
(e.g. Cronbach’s alpha, to assess quality of PROMs
responses). Open-ended patient feedback questions will
be examined qualitatively, as will the type of reasons
offered for non-consent and withdrawal, and the nature
of technical problems and patient difficulties with using
the system. The efficiency and practicality of the patient
recruitment procedures will also be examined qualita-
tively (including using process mapping tools and
software).
Secondary outcomes
If the system proves feasible, and a sufficient number of
patients provide data of satisfactory quality, we will ana-
lyse these data for two main purposes: (1) to explore
and check the psychometric properties (e.g. reliability,
validity) of the newer, less well-established PROMs
requiring of further psychometric analyses, and (2) to
assess and describe patients’ self-reported health and
quality-of-life outcomes, and explore if and how they
relate to disease, treatment and/or individual differences
characteristics.
Psychometric analyses will be undertaken using
descriptive statistics such as proportions and means (e.g.
to determine the presence of floor and ceiling effects),
measures of correlation (e.g. between responses to dif-
ferent PROMs to determine convergent and discrimi-
nant validity) and measures of internal reliability (e.g.
Cronbach’s alpha). The health and quality-of-life out-
comes reported by patients will be assessed and
described using statistics such as proportions, means
and standard deviations (e.g. sample means and stan-
dard deviations of PROMs scores) and t-tests (e.g. to
compare the sample scores with population norms). If
and how the outcomes relate to disease, treatment and/
or individual differences characteristics (e.g. sociodemo-
graphic and psychological variables) will be explored
using multiple and logistic regression analyses (e.g. to
explore if illness perceptions within 6 months of diagno-
sis are predictive of health outcomes 15 months post-
diagnosis) and/or analysis of variance (ANOVA) (e.g. to
examine if breast, colorectal and prostate cancer patients
experience significantly different levels of social difficul-
ties 9 months post-diagnosis).
Study organisation and management
The study research team and wider steering group col-
lectively includes expertise in psychosocial oncology
research, (electronic) PROMs, clinical oncology, nursing,
data management, statistics, epidemiology, health infor-
matics and cancer registration. The conduct and pro-
gress of the study will be discussed and reviewed in
fortnightly to monthly meetings of the core day-to-day
research team and chief investigator, and in quarterly
meetings of all study co-investigators/the wider steering
group. The steering group includes four patient repre-
sentatives, and we will provide verbal reports on the
study at biannual meetings of our wider research
group’s patient and carer Research Advisory Group. The
study is included in the UK National Institute for Health
Research (NIHR) Clinical Research Network (CRN)
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Portfolio, and we will provide monthly anonymised
reports on study accrual to the NIHR CRN office. We
will also provide regular reports on study recruitment
and progress to the National Cancer Research Institute
clinical studies groups (the breast, colorectal and pros-
tate cancer site-specific groups, and the psychosocial
oncology group).
Discussion
System usability for patients
Most cancer survivors are older (> 65 years) [10], with
associated lower levels of computer literacy [62]. How-
ever, we have borne this in mind during the develop-
ment of the ePOCS system, and worked with cancer
patients to include features which will enhance usability
for older adults and/or those with limited computer
skills. For example, all website and QTool webpages
have large-size text and navigation buttons, and QTool
saves answers to PROMs entirely automatically; a
detailed account of the system features included to
increase patient usability is provided elsewhere [19]. We
acknowledge that not all patients will be sufficiently
interested or enabled to use an internet-based system
like ePOCS. However, ePOCS is a future-focused sys-
tem, and the ‘digital divide’ is a diminishing problem. In
the UK, the number of internet-enabled households and
individuals is continually increasing; in 2010 73% of
households had internet access, compared with only
57% in 2006, and 73% of adults used the internet at
least weekly, relative to just 51% in 2006 [29]. However,
it is likely inevitable that, for the short-term future,
paper PROMs will have to be made available as a ‘back-
up’ option for a (ever-decreasing) proportion of patients.
The potential benefits and uses of the ePOCS system
This study aims to test the feasibility of an electronic
system in which PROMs are completed online and the
data are stored in cancer registries/the NCDR. As the
Internet and cancer registries both provide enduring
UK-wide coverage, such a system is feasibly sustainable
and UK-scalable. ePOCS has potential to provide a cost-
efficient technical platform to facilitate and support
longitudinal cohort research to improve understanding
of cancer survivors’ experiences. Improved understand-
ing of the challenges of survivorship will enable cancer
patients (if they wish) to receive more detailed, indivi-
dualised information about the symptoms and psychoso-
cial difficulties they may face ahead, based on the self-
reported experiences of other similar patients. It will
also inform service planning and facilitate the develop-
ment of tailored interventions for those patients who (or
who will likely) experience significant difficulties. The
ePOCS system could potentially be used by different
groups for different purposes. The system could be used
by university research groups, independently but simul-
taneously, to facilitate and support different PROMs-
based survivorship cohort studies. Alternatively, the sys-
tem could be used in a national government-supported
initiative to realise the NCSI goal of increased cancer
PROMs collection; if ePOCS is used in this way, the
resultant anonymised dataset could be made a national
resource, freely available on request for hypothesis-dri-
ven analyses.
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